Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy
Phase 2
Recruiting
- Conditions
- Immunoglobulin A Nephropathy
- Registration Number
- JPRN-jRCT2031220273
- Lead Sponsor
- Yano Hisako
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 600
Inclusion Criteria
1) Subjects who completed Trial 417-201-00007 or VIS649-201 without safety concerns and who, in the opinion of the investigator, could potentially benefit from treatment with sibeprenlimab.
2) eGFR >= 20 mL/min/1.73 m2, calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula.
Exclusion Criteria
1) Subjects who have not completed participation in trials 417-201-00007 or VIS649-201.
2) Subjects who, following enrollment in trials 417-201-00007 or VIS649-201 developed a condition or characteristic that would have excluded them from participation in these trials.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method